Last reviewed · How we verify
AN2690 Topical Solution, 5%
AN2690 is a topical antifungal that inhibits fungal squalene epoxidase, disrupting ergosterol synthesis in the fungal cell membrane.
AN2690 is a topical antifungal that inhibits fungal squalene epoxidase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Onychomycosis (fungal nail infection).
At a glance
| Generic name | AN2690 Topical Solution, 5% |
|---|---|
| Sponsor | Pfizer |
| Drug class | Topical antifungal (squalene epoxidase inhibitor) |
| Target | Squalene epoxidase |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The drug works by blocking squalene epoxidase, a key enzyme in the synthesis of ergosterol, which is essential for fungal cell membrane integrity. This leads to accumulation of toxic sterol precursors and fungal cell death. It is designed for topical application to treat fungal nail infections (onychomycosis).
Approved indications
- Onychomycosis (fungal nail infection)
Common side effects
- Application site irritation
- Erythema
- Pruritus at application site
Key clinical trials
- Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail (PHASE3)
- Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail (PHASE3)
- An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AN2690 Topical Solution, 5% CI brief — competitive landscape report
- AN2690 Topical Solution, 5% updates RSS · CI watch RSS
- Pfizer portfolio CI